16 September 2026 editorial review · Item
Leiden tolerogenic dendritic-cell therapy: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: reviewed; no confirmed content change. Current item
lastReviewed: 2026-08-27T00:00:00.000Z. - Claim check: LUMC's June first-recipient announcement reports no adverse effects in one person, not a safety database. The target n=10 and two-year follow-up are design features, not established durability. Detailed dynamic CTIS retrieval was limited.
- Primary publication/regulatory sources checked or consulted: 2023-508558-25-01?lang=en.